In patients with systolic heart failure (HF), blockade of the renin-angiotensin system has been shown to prolong survival and reduce adverse outcomes. 1 Angiotensin-converting–enzyme inhibitors (ACEi) have become a cornerstone in reducing the risk of HF, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or HF. 2 In this video, Dr. Mohan Bhargava discusses the prevalence of hypertension, the attributable risk of hypertension in HF, and the probability of HF. Dr.
Mohan Bhargava also discusses several clinical trials of ACEi in stable CAD and HF and in-depth mechanism of action of ACEi in reducing coronary artery events. References: PEACE Trial Investigators, New England Journal of Medicine. 2004 Nov 11;351(20):2058-68. Dagenais GR et al., The Lancet. 2006 Aug 12;368(9535):581-8.
